Intra-Nasal Administration of the OM-85 Bacterial Lysate Strongly Protects from Experimental Asthma by Targeting Multiple Innate and Adaptive Immune Processes

被引:0
|
作者
Pivniouk, V. [1 ]
Gimenes, J. A., Jr. [2 ]
Ezeh, P. [2 ]
Michael, A. N. [2 ]
Pivniouk, O. [2 ]
Abidov, A. [3 ]
Gozdz, J. [2 ]
DeVries, A. [2 ]
Pasquali, C. [4 ]
Vercelli, D. [1 ]
机构
[1] Univ Arizona, Dept Cellular & Mol Med, Asthma & Airway Dis Res Ctr, Tucson, AZ USA
[2] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA
[3] Univ Arizona, Coll Med, Med Student Res Program, Tucson, AZ USA
[4] OM Pharma SA, Geneva, Switzerland
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A1058
引用
收藏
页数:2
相关论文
共 1 条
  • [1] Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis
    Pivniouk, Vadim
    Gimenes-Junior, Joao A., Jr.
    Ezeh, Peace
    Michael, Ashley
    Pivniouk, Oksana
    Hahn, Seongmin
    VanLinden, Sydney R.
    Malone, Sean P.
    Abidov, Amir
    Anderson, Dayna
    Gozdz, Justyna
    DeVries, Avery
    Martinez, Fernando D.
    Pasquali, Christian
    Vercelli, Donata
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 943 - 956